Literature DB >> 11202454

18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels.

S Hoegerle1, C Altehoefer, N Ghanem, I Brink, E Moser, E Nitzsche.   

Abstract

In spite of the availability of numerous procedures, diagnostic imaging of tumour manifestations in patients with medullary thyroid carcinoma and elevated calcitonin levels is often difficult. In the present study, the new procedure of fluorine-18 dihydroxyphenylalanine positron emission tomography (18F-DOPA PET) was compared with the established functional and morphological imaging methods. After evaluation of the normal distribution of 18F-DOPA, 11 patients with medullary thyroid carcinoma were examined using 18F-DOPA PET. Results of 18F-fluorodeoxyglucose (18F-FDG) PET, somatostatin receptor scintigraphy (SRS) and morphological tomographic imaging (CT/MRI) were available for all patients. All individual procedures were evaluated without reference to prior information. Data assessment for each patient was based on cooperation between experienced radiologists and specialists in nuclear medicine, who considered all the available findings (histological results, imaging, follow-up studies). This cooperation served as the gold standard against which the results of the individual procedures were evaluated. A total of 27 tumours were studied [three primary tumours (PT)/local recurrence (LR), 16 lymph node metastases (LNM) and eight organ metastases (OM)]. 18F-DOPA PET produced 17 true-positive findings (2 PT/LR, 14 LNM, 1 OM), 18F-FDG PET 12 (2 PT/LR, 7 LNM, 3 OM), SRS 14 (2 PT/LR, 8 LNM, 4 OM) and morphological imaging 22 (3 PT/LR, 11 LNM, 8 OM). The following sensitivities were calculated with respect to total tumour manifestations: 18F-DOPA PET 63%, 18F-FDG PET 44%, SRS 52%, morphological imaging 81%. Thus, the morphological imaging procedures produce the best overall sensitivity, but the specificity for PT/LR (55%) and LNM (57%) was low. With respect to lymph node staging, the best results were obtained with 18F-DOPA PET. 18F-DOPA PET is a new functional imaging procedure for medullary thyroid carcinoma that seems to provide better results than SRS and 18F-FDG PET. Moreover, the data indicate that no single procedure provides adequate diagnostic certainty. Therefore, 18F-DOPA PET is a useful supplement to morphological diagnostic imaging, improving lymph node staging and enabling a more specific diagnosis of primary tumour and local recurrence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11202454     DOI: 10.1007/s002590000404

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  47 in total

1.  Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study.

Authors:  Arnoldo Piccardo; Egesta Lopci; Massimo Conte; Alberto Garaventa; Luca Foppiani; Vania Altrinetti; Cristina Nanni; Pietro Bianchi; Angela Cistaro; Stefania Sorrentino; Manlio Cabria; Andrea Pession; Matteo Puntoni; Giampiero Villavecchia; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-20       Impact factor: 9.236

2.  Evolving paradigms for successful molecular imaging of medullary thyroid carcinoma.

Authors:  Domenico Rubello; Ka Kit Wong; Maria Cristina Marzola; Mohsen Beheshti; Valentina Ambrosini; Sotirios Chondrogiannis; Milton D Gross
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04       Impact factor: 9.236

3.  Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component.

Authors:  Patrick Veit-Haibach; Marc Schiesser; Jan Soyka; Klaus Strobel; Niklaus G Schaefer; Rolf Hesselmann; P-A Clavien; Thomas F Hany
Journal:  Eur Radiol       Date:  2010-08-15       Impact factor: 5.315

4.  18F-DOPA PET/CT and neuroendocrine tumours.

Authors:  Cristina Nanni; Domenico Rubello; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05       Impact factor: 9.236

5.  (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma.

Authors:  Valentina Ambrosini; Maria Cristina Marzola; Domenico Rubello; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

Review 6.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

7.  68Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with 111In-octreotide SPECT/CT and conventional imaging.

Authors:  Lilian Yuri Itaya Yamaga; Marcelo L Cunha; Guilherme C Campos Neto; Marcio R T Garcia; Ji H Yang; Cleber P Camacho; Jairo Wagner; Marcelo B G Funari
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-20       Impact factor: 9.236

8.  Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy.

Authors:  Hyemi Kwon; Won Gu Kim; Min Ji Jeon; Dong Eun Song; Yu-Mi Lee; Tae-Yon Sung; Ki-Wook Chung; Jong Ho Yoon; Suck Joon Hong; Jung Hwan Baek; Jeong Hyun Lee; Tae Yong Kim; Won Bae Kim; Young Kee Shong
Journal:  Endocrine       Date:  2016-01-11       Impact factor: 3.633

Review 9.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

10.  Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results.

Authors:  Thierry Jacob; Dany Grahek; Nassima Younsi; Khaldoun Kerrou; Nicolas Aide; Françoise Montravers; Sonia Balogova; Cecile Colombet; Virginie De Beco; Jean N Talbot
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.